{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T13:42:08Z","timestamp":1758634928654,"version":"3.37.3"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,1,18]],"date-time":"2019-01-18T00:00:00Z","timestamp":1547769600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cardiovasc Disord"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s12872-018-0994-y","type":"journal-article","created":{"date-parts":[[2019,1,18]],"date-time":"2019-01-18T08:02:56Z","timestamp":1547798576000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Clinical results of bioresorbable drug-eluting scaffolds in short and long coronary artery lesions using the PSP technique"],"prefix":"10.1186","volume":"19","author":[{"given":"Christine","family":"Reichart","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9915-1815","authenticated-orcid":false,"given":"Jochen","family":"W\u00f6hrle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sinisa","family":"Markovic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wolfgang","family":"Rottbauer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia","family":"Seeger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,1,18]]},"reference":[{"issue":"10059","key":"994_CR1","doi-asserted-by":"publisher","first-page":"2479","DOI":"10.1016\/S0140-6736(16)32050-5","volume":"388","author":"PW Serruys","year":"2016","unstructured":"Serruys PW, Chevalier B, Sotomi Y, et al. Comparison of an everolimus-eluting bioresorbable scaffold with an everolimus-eluting metallic stent for the treatment of coronary artery stenosis (ABSORB II): a 3 year, randomised, controlled, single-blind, multicentre clinical trial. Lancet. 2016;388(10059):2479\u201391.","journal-title":"Lancet"},{"key":"994_CR2","doi-asserted-by":"crossref","unstructured":"Ellis SG, Kereiakes DJ, Metzger DC, et al. Everolimus-eluting Bioresorbable scaffolds for coronary artery disease. N Engl J Med. 2015;373(20).","DOI":"10.1056\/NEJMoa1509038"},{"issue":"24","key":"994_CR3","doi-asserted-by":"publisher","first-page":"2319","DOI":"10.1056\/NEJMoa1614954","volume":"376","author":"JJ Wykrzykowska","year":"2017","unstructured":"Wykrzykowska JJ, Kraak RP, Hofma SH, et al. AIDA investigators. Bioresorbable scaffolds versus metallic stents in routine PCI. N Engl J Med. 2017;376(24):2319\u201328.","journal-title":"N Engl J Med"},{"issue":"8","key":"994_CR4","first-page":"921","volume":"67","author":"S Puricel","year":"2016","unstructured":"Puricel S, Cuculi F, Weissner M, et al. Bioresorbable coronary scaffold thrombosis. Multicenter Comprehensive Analysis of Clinical Presentation, Mechanisms, and Predictors J Am Coll Cardiol. 2016;67(8):921\u201331.","journal-title":"Multicenter Comprehensive Analysis of Clinical Presentation, Mechanisms, and Predictors J Am Coll Cardiol"},{"issue":"2","key":"994_CR5","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1097\/MCA.0000000000000449","volume":"28","author":"C Kugler","year":"2017","unstructured":"Kugler C, Markovic S, Rottbauer W, et al. Bioresorbable scaffolds compared with everolimus-eluting stents for the treatment of chronic coronary total occlusion: clinical and angiographic results of a matched paired comparison. Coron Artery Dis. 2017;28(2):120\u20135.","journal-title":"Coron Artery Dis"},{"issue":"12","key":"994_CR6","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.1016\/j.amjcard.2017.03.017","volume":"119","author":"B Cortese","year":"2017","unstructured":"Cortese B, Ielasi A, Moscarella E, et al. RAI investigators. Thirty-day outcomes after unrestricted implantation of Bioresorbable vascular scaffold (from the prospective RAI registry). Am J Cardiol. 2017;119(12):1924\u201330.","journal-title":"Am J Cardiol"},{"issue":"7","key":"994_CR7","doi-asserted-by":"publisher","first-page":"E493","DOI":"10.1002\/ccd.27657","volume":"92","author":"JF D\u00edaz Fern\u00e1ndez","year":"2018","unstructured":"D\u00edaz Fern\u00e1ndez JF, Camacho Freire SJ, Fern\u00e1ndez Guerrero JC, et al. Everolimus drug-eluting stent performance in patients with long coronary lesions: the multicenter Longprime registry. Catheter Cardiovasc Interv. 2018;92(7):E493\u2013501. \n                    https:\/\/doi.org\/10.1002\/ccd.27657\n                    \n                  . Epub 2018 May 18.","journal-title":"Catheter Cardiovasc Interv"},{"issue":"1","key":"994_CR8","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1111\/joic.12262","volume":"29","author":"M Lesiak","year":"2016","unstructured":"Lesiak M, Araszkiewicz A, Grajek S, et al. Long coronary lesions treated with thin strut Bioresorbable polymer drug eluting stent: experience from multicentre randomized CENTURY II study. J Interv Cardiol. 2016;29(1):47\u201356. \n                    https:\/\/doi.org\/10.1111\/joic.12262\n                    \n                  .","journal-title":"J Interv Cardiol"},{"key":"994_CR9","doi-asserted-by":"publisher","unstructured":"Kang DY, Lee CH, Lee PH, et al. Comparison of resolute zotarolimus-eluting and Xience everolimus-eluting stents in patients with de novo long coronary artery lesions: a randomized LONG-DES VI trial. Coron Artery Dis. 2018. \n                    https:\/\/doi.org\/10.1097\/MCA.0000000000000680\n                    \n                  . [Epub ahead of print].","DOI":"10.1097\/MCA.0000000000000680"},{"key":"994_CR10","doi-asserted-by":"publisher","unstructured":"Patra S, Chakraborty RN, Pande A, et al. Zotarolimus-eluting Resolute Integrity versus everolimus-eluting Xience Xpedition stents in the management of very long (>30mm) de novo coronary artery stenosis. Cardiovasc Revasc Med. 2017;18(3):160\u2013164. \n                    https:\/\/doi.org\/10.1016\/j.carrev.2016.12.007\n                    \n                  . Epub 2016 Dec 15.","DOI":"10.1016\/j.carrev.2016.12.007"},{"issue":"2","key":"994_CR11","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.jcin.2010.09.024","volume":"4","author":"Y Morino","year":"2011","unstructured":"Morino Y, Abe M, Morimoto T, et al. Predicting successful guidewire crossing through chronic total occlusion of native coronary lesions within 30 minutes: the J-CTO (multicenter CTO registry in Japan) score as a difficulty grading and time assessment tool. JACC Cardiovasc Interv. 2011;4(2):213\u201321.","journal-title":"JACC Cardiovasc Interv."},{"issue":"8","key":"994_CR12","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.1016\/S0735-1097(01)01344-4","volume":"37","author":"SC Smith Jr","year":"2001","unstructured":"Smith SC Jr, Dove JT, Jacobs AK, et al. ACC\/AHA guidelines for percutaneous coronary intervention (revision of the 1993 PTCA guidelines) - executive summary: a report of the American College of Cardiology\/American Heart Association task force on practice guide-lines (committee to revise the 1993 guidelines for percutaneous transluminal coronary angioplasty) endorsed by the society for cardiac angiography and interventions. J Am Coll Cardiol. 2001;37(8):2215\u201339.","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"994_CR13","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/j.jcin.2012.12.131","volume":"6","author":"V Farooq","year":"2013","unstructured":"Farooq V, Serruys PW, Heo JH, et al. Intracoronary optical coherence tomography and histology of overlapping everolimus-eluting bioresorbable vascular scaffolds in a porcine coronary artery model the potential implications for clinical practice. JACC Cardiovasc Interv. 2013;6(5):523\u201332.","journal-title":"JACC Cardiovasc Interv"},{"issue":"17","key":"994_CR14","doi-asserted-by":"publisher","first-page":"2344","DOI":"10.1161\/CIRCULATIONAHA.106.685313","volume":"115","author":"DE Cutlip","year":"2007","unstructured":"Cutlip DE, Windecker S, Mehran R, et al. Academic research consortium. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation. 2007;115(17):2344\u201351.","journal-title":"Circulation"},{"issue":"9962","key":"994_CR15","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/S0140-6736(14)61455-0","volume":"385","author":"PW Serruys","year":"2015","unstructured":"Serruys PW, Chevalier B, Dudek D, et al. A bioresorbable everolimus-eluting scaffold versus a metallic everolimus-eluting stent for ischaemic heart disease caused by de-novo native coronary artery lesions (ABSORB II): an interim 1-year analysis of clinical and procedural secondary outcomes from a randomised controlled trial. Lancet. 2015;385(9962):43\u201354.","journal-title":"Lancet"},{"issue":"21","key":"994_CR16","doi-asserted-by":"publisher","first-page":"2298","DOI":"10.1016\/j.jacc.2015.09.054","volume":"66","author":"R Gao","year":"2015","unstructured":"Gao R, Yang Y, Han Y, et al. Bioresorbable vascular scaffolds versus metallic stents in patients with coronary artery disease. ABSORB China trial J Am Coll Cardiol. 2015;66(21):2298\u2013309.","journal-title":"ABSORB China trial J Am Coll Cardiol"},{"issue":"47","key":"994_CR17","doi-asserted-by":"publisher","first-page":"3332","DOI":"10.1093\/eurheartj\/ehv435","volume":"36","author":"T Kimura","year":"2015","unstructured":"Kimura T, Kozuma K, Tanabe K, et al. A randomized trial evaluating everolimus-eluting Absorb bioresorbable scaffolds vs. everolimus-eluting metallic stents in patients with coronary artery disease: ABSORB Japan. Eur Heart J. 2015;36(47):3332\u201342.","journal-title":"Eur Heart J"},{"key":"994_CR18","doi-asserted-by":"publisher","unstructured":"Costa JR Jr, Abizaid A, Whitbourn R, ABSORB EXTEND investigators et al. three-year clinical outcomes of patients treated with everolimus-eluting bioresorbable vascular scaffolds: final results of the ABSORB EXTEND trial. Catheter Cardiovasc Interv 2018. \n                    https:\/\/doi.org\/10.1002\/ccd.27715\n                    \n                  . [Epub ahead of print].","DOI":"10.1002\/ccd.27715"},{"issue":"10","key":"994_CR19","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.4244\/EIJY14M07_11","volume":"10","author":"D Capodanno","year":"2015","unstructured":"Capodanno D, Gori T, Nef H, et al. Percutaneous coronary intervention with everolimus-eluting bioresorbable vascular scaffolds in routine clinical practice: early and midterm outcomes from the European multicentre GHOST-EU registry. EuroIntervention. 2015;10(10):1144\u201353.","journal-title":"EuroIntervention"},{"issue":"14","key":"994_CR20","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.4244\/EIJV12I14A277","volume":"12","author":"K Yamaji","year":"2017","unstructured":"Yamaji K, R\u00e4ber L, Windecker S. What determines long-term outcomes using fully bioresorbable scaffolds - the device, the operator or the lesion? EuroIntervention. 2017;12(14):1684\u20137.","journal-title":"EuroIntervention"},{"issue":"10018","key":"994_CR21","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/S0140-6736(15)00979-4","volume":"387","author":"S Cassese","year":"2016","unstructured":"Cassese S, Byrne RA, Ndrepepa G, et al. Everolimus-eluting bioresorbable vascular scaffolds versus everolimus-eluting metallic stents: a meta-analysis of randomised controlled trials. Lancet. 2016;387(10018):537\u201344.","journal-title":"Lancet"},{"issue":"10025","key":"994_CR22","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1016\/S0140-6736(15)01039-9","volume":"387","author":"GW Stone","year":"2016","unstructured":"Stone GW, Gao R, Kimura T, et al. 1-year outcomes with the Absorb bioresorbable scaffold in patients with coronary artery disease: a patient-level, pooled meta-analysis. Lancet. 2016;387(10025):1277\u201389.","journal-title":"Lancet"},{"issue":"1","key":"994_CR23","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.jcin.2015.09.024","volume":"9","author":"MJ Lipinski","year":"2016","unstructured":"Lipinski MJ, Escarcega RO, Baker NC, et al. Scaffold thrombosis after percutaneous coronary intervention with ABSORB Bioresorbable vascular scaffold. A Systematic Review and Meta-Analysis JACC Cardiovasc Interv. 2016;9(1):12\u201324.","journal-title":"A Systematic Review and Meta-Analysis JACC Cardiovasc Interv"},{"issue":"18","key":"994_CR24","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1016\/j.jcin.2017.07.034","volume":"10","author":"A Polimeni","year":"2017","unstructured":"Polimeni A, Weissner M, Schochlow K, et al. Incidence, clinical presentation, and predictors of clinical restenosis in coronary Bioresorbable scaffolds. JACC Cardiovasc Interv. 2017;10(18):1819\u201327. \n                    https:\/\/doi.org\/10.1016\/j.jcin.2017.07.034\n                    \n                  .","journal-title":"JACC Cardiovasc Interv."},{"issue":"5","key":"994_CR25","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1097\/MCA.0000000000000618","volume":"29","author":"J W\u00f6hrle","year":"2018","unstructured":"W\u00f6hrle J, Nef HM, Naber C, et al. For the GABI-R study group. Predictors of early scaffold thrombosis: results from the multicenter prospective German-Austrian ABSORB RegIstRy. Coron Artery Dis. 2018;29(5):389\u201396.","journal-title":"Coron Artery Dis"},{"issue":"14","key":"994_CR26","doi-asserted-by":"publisher","first-page":"1730","DOI":"10.4244\/EIJ-D-16-00247","volume":"12","author":"A Tanaka","year":"2017","unstructured":"Tanaka A, Latib A, Kawamoto H, et al. Clinical outcomes of a real world cohort following bioresorbable vascular scaffold implantation utilising an optimized implantation strategy. EuroIntervention. 2017;12(14):1730\u20137.","journal-title":"EuroIntervention"},{"issue":"14","key":"994_CR27","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.4244\/EIJ-D-16-00471","volume":"12","author":"Y Sotomi","year":"2017","unstructured":"Sotomi Y, Suwannasom P, Serruys PW, et al. Possible mechanical causes of scaffold thrombosis: insights from case reports with intracoronary imaging. EuroIntervention. 2017;12(14):1747\u201356.","journal-title":"EuroIntervention"},{"issue":"Suppl 9","key":"994_CR28","doi-asserted-by":"publisher","first-page":"S914","DOI":"10.21037\/jtd.2017.06.35","volume":"9","author":"S Biscaglia","year":"2017","unstructured":"Biscaglia S, Erriquez A, Bernucci D, et al. BRS implantation in long lesions requiring device overlapping: myth or reality? J Thorac Dis. 2017;9(Suppl 9):S914\u201322. \n                    https:\/\/doi.org\/10.21037\/jtd.2017.06.35\n                    \n                  .","journal-title":"J Thorac Dis"},{"key":"994_CR29","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.ijcard.2018.04.081.","volume":"268","author":"A Polimeni","year":"2018","unstructured":"Polimeni A, Anadol R, M\u00fcnzel T, et al. Predictors of bioresorbable scaffold failure in STEMI patients at 3\u00a0years follow-up. Int J Cardiol. 2018;268:68\u201374. \n                    https:\/\/doi.org\/10.1016\/j.ijcard.2018.04.081.\n                    \n                  .","journal-title":"Int J Cardiol"},{"key":"994_CR30","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.ijcard.2018.06.094","volume":"270","author":"D Regazzoli","year":"2018","unstructured":"Regazzoli D, Latib A, Ezhumalai B, et al. Long-term follow-up of BVS from a prospective multicenter registry: impact of a dedicated implantation technique on clinical outcomes. Int J Cardiol. 2018;270:113\u20137. \n                    https:\/\/doi.org\/10.1016\/j.ijcard.2018.06.094\n                    \n                  . Epub 2018 Jun 25.","journal-title":"Int J Cardiol"},{"issue":"1","key":"994_CR31","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/s12872-018-0811-7.","volume":"18","author":"R Anadol","year":"2018","unstructured":"Anadol R, Schnitzler K, Lorenz L, et al. Three-years outcomes of diabetic patients treated with coronary bioresorbable scaffolds. BMC Cardiovasc Disord. 2018;18(1):92. \n                    https:\/\/doi.org\/10.1186\/s12872-018-0811-7\n                    \n                  .","journal-title":"BMC Cardiovasc Disord"},{"issue":"6","key":"994_CR32","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1016\/j.cjca.2018.02.030","volume":"34","author":"K Haddad","year":"2018","unstructured":"Haddad K, Tanguay JF, Potter BJ, et al. Longer inflation duration and Predilation-sizing-Postdilation improve Bioresorbable scaffold outcomes in a long-term all-comers Canadian registry. Can J Cardiol. 2018;34(6):752\u20138. \n                    https:\/\/doi.org\/10.1016\/j.cjca.2018.02.030\n                    \n                   Epub 2018 Mar 12.","journal-title":"Can J Cardiol"},{"issue":"23","key":"994_CR33","doi-asserted-by":"publisher","first-page":"2363","DOI":"10.1016\/j.jcin.2017.08.020","volume":"10","author":"T Gori","year":"2017","unstructured":"Gori T, Weissner M, G\u00f6nner S, et al. Characteristics, predictors, and mechanisms of thrombosis in coronary Bioresorbable scaffolds. Differences Between Early and Late Events JACC Cardiovasc Interv. 2017;10(23):2363\u201371. \n                    https:\/\/doi.org\/10.1016\/j.jcin.2017.08.020\n                    \n                  .","journal-title":"Differences Between Early and Late Events JACC Cardiovasc Interv"},{"issue":"12","key":"994_CR34","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1016\/j.jcin.2017.04.001.","volume":"10","author":"S Biscaglia","year":"2017","unstructured":"Biscaglia S, Campo G. Bioresorbable Everolimus-eluting vascular scaffold for long coronary lesions: a subanalysis of the international, multicenter GHOST-EU (gauging coronary healing with bioresorbable scaffolding plaTforms in EUrope) registry. JACC Cardiovasc Interv. 2017;10(12):1274\u20135. \n                    https:\/\/doi.org\/10.1016\/j.jcin.2017.04.001\n                    \n                  .","journal-title":"JACC Cardiovasc Interv."},{"issue":"9","key":"994_CR35","doi-asserted-by":"publisher","first-page":"e1011","DOI":"10.4244\/EIJ-D-17-00410","volume":"14","author":"R Anadol","year":"2018","unstructured":"Anadol R, Lorenz L, Weissner M, et al. Characteristics and outcome of patients with complex coronary lesions treated with bioresorbable scaffolds: three-year follow-up in a cohort of consecutive patients. EuroIntervention. 2018;14(9):e1011\u20139. \n                    https:\/\/doi.org\/10.4244\/EIJ-D-17-00410\n                    \n                  .","journal-title":"EuroIntervention"},{"key":"994_CR36","doi-asserted-by":"publisher","DOI":"10.1186\/s12872-015-0163-5","volume":"15","author":"S Sorrentino","year":"2015","unstructured":"Sorrentino S, De Rosa S, Ambrosio G, et al. The duration of balloon inflation affects the luminal diameter of coronary segments after bioresorbable vascular scaffolds deployment. BMC Cardiovasc Disord. 2015;15:169. \n                    https:\/\/doi.org\/10.1186\/s12872-015-0163-5\n                    \n                  .","journal-title":"BMC Cardiovasc Disord"},{"issue":"1\u20132","key":"994_CR37","doi-asserted-by":"publisher","first-page":"3","DOI":"10.3233\/CH-189101","volume":"69","author":"R Anadol","year":"2018","unstructured":"Anadol R, Dimitriadis Z, Polimeni A, et al. Bioresorbable everolimus-eluting vascular scaffold for patients presenting with non STelevation-acute coronary syndrome: a three-years follow-up1. Clin Hemorheol Microcirc. 2018;69(1\u20132):3\u20138. \n                    https:\/\/doi.org\/10.3233\/CH-189101\n                    \n                  .","journal-title":"Clin Hemorheol Microcirc"},{"key":"994_CR38","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.ijcard.2016.01.202","volume":"208","author":"S Biscaglia","year":"2016","unstructured":"Biscaglia S, Ugo F, Ielasi A, et al. Bioresorbable scaffold vs. second generation drug eluting stent in long coronary lesions requiring overlap: a propensity-matched comparison (the UNDERDOGS study). Int J Cardiol. 2016;208:40\u20135.","journal-title":"Int J Cardiol"},{"issue":"12","key":"994_CR39","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1016\/j.rec.2016.08.012","volume":"69","author":"J Wiebe","year":"2016","unstructured":"Wiebe J, D\u00f6rr O, Liebetrau C, et al. Outcome after long-segment stenting with Everolimus-eluting Bioresorbable scaffolds focusing on the concept of overlapping implantation. Rev Esp Cardiol (Engl Ed). 2016;69(12):1144\u201351. \n                    https:\/\/doi.org\/10.1016\/j.rec.2016.08.012\n                    \n                  . Epub 2016 Oct 27.","journal-title":"Rev Esp Cardiol (Engl Ed)"},{"issue":"6","key":"994_CR40","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1016\/j.jcin.2016.12.013","volume":"10","author":"S Geraci","year":"2017","unstructured":"Geraci S, Kawamoto H, Caramanno G. Et a.. Bioresorbable Everolimus-eluting vascular scaffold for long coronary lesions: a subanalysis of the international, multicenter GHOST-EU registry. JACC Cardiovasc Interv. 2017;10(6):560\u20138. \n                    https:\/\/doi.org\/10.1016\/j.jcin.2016.12.013\n                    \n                  . Epub 2017 Mar 1.","journal-title":"JACC Cardiovasc Interv."}],"container-title":["BMC Cardiovascular Disorders"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-018-0994-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12872-018-0994-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-018-0994-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,1,17]],"date-time":"2020-01-17T19:12:05Z","timestamp":1579288325000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccardiovascdisord.biomedcentral.com\/articles\/10.1186\/s12872-018-0994-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,18]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["994"],"URL":"https:\/\/doi.org\/10.1186\/s12872-018-0994-y","relation":{},"ISSN":["1471-2261"],"issn-type":[{"type":"electronic","value":"1471-2261"}],"subject":[],"published":{"date-parts":[[2019,1,18]]},"assertion":[{"value":"8 October 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 December 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 January 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the ethics committee of the University of Ulm, Ulm, Germany (reference number 241\/13).Written informed consent was obtained from all patients.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"22"}}